Strategic partnerships Leverage ExeVir's VHH-Fc platform and broad-spectrum lead candidate to propose collaborations with vaccine developers, infectious disease programs, or public health initiatives seeking next-generation antibody therapeutics with pan-disease potential.

Damper-resistant value Position the company’s variant-proof and long-acting antibody approach as a differentiated solution for immunocompromised and elderly patient populations, highlighting durable protection that complements existing therapies.

Pipeline inflection Target opportunities around COVID-19 and dengue programs while monitoring expansion into multi-specific constructs, offering CDMO or co-development services to accelerate preclinical to clinical milestones.

Funding signals Capitalize on recent venture debt from EIB and Series A momentum as proof points for investor confidence; approach strategic investors and pharma partnerships that value early-stage biotech with scalable manufacturing and clear clinical pathways.

Operational readiness Highlight ExeVir’s Belgian headquarters, experienced leadership hires, and established discovery and production capabilities as a near-term partner for contract development and manufacturing (CDMO) discussions to support fast-track programs.